drugset / Trial / NCT00112476

Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT00112476

Phase 1 Completed 24 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of temsirolimus when given together with bryostatin 1 in treating patients with unresectable or metastatic solid tumors. Drugs used in chemotherapy, such as temsirolimus and bryostatin 1, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Timeline

Start
2005-03
Primary completion
2010-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Temsirolimus Small molecule Intravenous
Subject bryostatin 1 Small molecule Intravenous